Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

820
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
820
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

2.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.6K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

851
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
851
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

505
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
505

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From clinical trial to clinical experience: Lecanemab therapy in a real-world case series.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Home-based, virtually supported multimodal prehabilitation compared with usual care prior to major surgery: a multicentre, pragmatic pilot randomised trial.

BJA open·2026
Same author

OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.

Hepatology (Baltimore, Md.)·2026
Same author

Supporting Youth from Pediatric- to Adult-Oriented HIV Care Across Two Metro Sites in the United States: Results from the <i>iTransition</i> Pilot Trial.

AIDS patient care and STDs·2026
Same author

Evaluation of Functional T-Cell Assays That Predict Causal Allergens in Eosinophilic Esophagitis.

Diagnostics (Basel, Switzerland)·2026
Same author

Home-Based Prehabilitation for Older Surgical Patients With Frailty: A Randomized Clinical Trial.

JAMA surgery·2025
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Advancements and Challenges in Machine Perfusion for Liver Transplantation
05:25

Author Spotlight: Advancements and Challenges in Machine Perfusion for Liver Transplantation

Published on: June 14, 2024

392

Preventing Readmissions for Hepatic Encephalopathy.

Salima S Makhani1, Susan Lee2, David Bernstein3

  • 1Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, Manhasset, NY 11030, USA.

Clinics in Liver Disease
|March 28, 2024
PubMed
Summary
This summary is machine-generated.

Hepatic encephalopathy (HE) frequently causes hospital readmissions in advanced liver disease patients. Preventing HE readmissions through multidisciplinary, patient-centered care improves quality of life and reduces healthcare costs.

Keywords:
CirrhosisEncephalopathyPreventionReadmissionRifaximin

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

417
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

Author Spotlight: Advancements and Challenges in Machine Perfusion for Liver Transplantation
05:25

Author Spotlight: Advancements and Challenges in Machine Perfusion for Liver Transplantation

Published on: June 14, 2024

392
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

417
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Hepatic encephalopathy (HE) is a significant predictor of hospital readmissions in patients with advanced liver disease.
  • Recurrent HE and readmissions can lead to irreversible organ dysfunction, reduced quality of life, and increased healthcare costs.

Purpose of the Study:

  • To highlight the preventability of many HE-related hospital readmissions.
  • To emphasize the importance of multidisciplinary, patient-centered care throughout the patient continuum.
  • To underscore the necessity of understanding outpatient daily functions and limitations in managing HE.

Main Methods:

  • Review of existing literature on hepatic encephalopathy management and readmission factors.
  • Analysis of patient care pathways and the impact of multidisciplinary interventions.
  • Focus on outpatient assessment to identify triggers for inpatient admission.

Main Results:

  • Hepatic encephalopathy is a major driver of readmissions in advanced liver disease.
  • A substantial portion of HE readmissions are preventable with appropriate interventions.
  • Understanding patient's daily life in the outpatient setting is crucial for preventing hospitalizations.

Conclusions:

  • Multidisciplinary, patient-centered care is essential for managing HE and reducing readmissions.
  • Proactive outpatient management, considering daily patient functions, can mitigate HE exacerbations and hospitalizations.
  • Effective HE management improves patient outcomes and reduces the economic burden on healthcare systems.